
1. postepy hig med dosw (online). 2015 dec 31;69:1411-22.

[viral transfer tumor necrosis factor-related apoptosis-inducing ligand
(trail) gene therapy].

[article polish]

wędrowska e(1), wandtke t(1), dyczek a(2), woźniak j(1).

author information: 
(1)zakład genoterapii, collegium medicum, uniwersytet mikołaja kopernika,
bydgoszcz/toruń
(2)konsultacyjna przychodnia specjalistyczna kardiologiczna kardiochirurgiczna,
krakowski szpital specjalistyczny im. jana pawła ii.

tumor necrosis factor-related apoptosis-inducing ligand (trail) selectively
induces carcinoma cell death extrinsic pathway apoptosis.
preclinical trials gene therapy conducted using viral transfer of
the trail transgene prostate, bladder, breast, kidney, liver, non-small cell
lung cancer also glioblastoma cells. experiments vitro demonstrated the
extensive apoptosis target cells well frequent disease regression or
remission. trail transfer show side effects, opposite to
chemotherapy. encouraging results trail-related gene therapy observed 
rheumatoid arthritis type 1 diabetes. adenoviral vectors (adv) encoding trail
are promising tool anti-tumor therapy. undergone numerous
modifications increasing transfection efficiency transgene expression in
target cells. however, one clinical phase trial performed. adv
encoding trail transgene caused local inflammation apoptosis patients 
with prostate cancer.


pmid: 27259213  [indexed medline]

